Novo Holdings
Danish investment firm reportedly participating in Mistral AI's funding round.
Novo Holdings is the Danish investment firm behind Novo Nordisk, reported on 22 July 2026 as a potential co-investor in a fresh, unclosed funding round for Mistral AI.
Last refreshed: 26 July 2026 · Appears in 1 active topic
Is Danish pharma money now backing Europe's answer to OpenAI through Mistral?
Timeline for Novo Holdings
Reported co-investor in Mistral AI's funding round
European Tech Sovereignty: Samsung in talks to anchor Mistral at €20bn valuationBackground
Novo Holdings is a Danish investment firm, founded in 1999, that manages the assets of the Novo Nordisk Foundation and holds controlling stakes in Novo Nordisk and Novonesis. It ran roughly €93 billion in assets at the end of 2025, across more than 180 direct investments concentrated in life sciences, from offices in Copenhagen, San Francisco, Boston, London, Singapore and Shanghai.
Backing a French AI lab sits well outside that pattern: Novo Holdings' money has historically gone into pharmaceuticals and biotech, not chips or foundation models. Reporting on 22 July 2026 placed the firm among the names circling Mistral AI's latest funding push, alongside a Korean electronics giant and a European private-equity fund, at a reported valuation of about €20 billion .
That round remained open rather than closed as of 22 July 2026, and Novo Holdings' involvement is reported rather than confirmed; the firm has made no public statement on the talks.